The mRNA vaccines used to prevent COVID-19 appear to be highly effective against variants of concern, in contrast to the reduced efficacy seen with other vaccine technologies. Read More
Latest News
mRNA vaccines preferred: new NACI recommendation
May 5, 2021The National Advisory Committee on Immunization (NACI) is now recommending that Canadians wait for an mRNA vaccine if they can rather than take the first COVID vaccine they can get (www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html). Read More
MS Clinics Network updates COVID vaccine guidance
May 3, 2021The Canadian Network of MS Clinics has updated its COVID vaccine recommendations following a report of a reduced vaccine response in MS patients receiving fingolimod or ocrelizumab (see Few vaccine responders with fingolimod, ocrelizumab, NeuroSens, April 23, 2021). Read More
Thrombotic risk and COVID-19 vaccines: new data and disputes
April 29, 2021An Oxford University study reports that the incidence of a rare clotting complication, cerebral venous sinus thrombosis (CVST or CVT), is significantly higher with COVID-19 infection compared to after COVID-19 vaccination (Taquet et al. OSF preprint, 14 April 2021; https://osf.io/a9jdq/). The study has not been peer reviewed. Read More